RELA is sufficient to mediate interleukin‐1 repression of androgen receptor expression and activity in an LNCaP disease progression model
- 15 November 2019
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 80 (2) , 133-145
Abstract
Background: The androgen receptor (AR) nuclear transcription factor is a therapeutic target for prostate cancer (PCa). Unfortunately, patients can develop resistance to AR‐targeted therapies and progress to lethal disease, underscoring the importance of understanding the molecular mechanisms that underlie treatment resistance. Inflammation is implicated in PCa initiation and progression and we have previously reported that the inflammatory cytokine, interleukin‐1 (IL‐1), represses AR messenger RNA (mRNA) levels and activity in AR‐positive (AR+) PCa cell lines concomitant with the upregulation of prosurvival biomolecules. Thus, we contend that IL‐1 can select for AR‐independent, treatment‐resistant PCa cells.Methods: To begin to explore how IL‐1 signaling leads to the repression of AR mRNA levels, we performed comprehensive pathway analysis on our RNA sequencing data from IL‐1‐treated LNCaP PCa cells. Our pathway analysis predicted nuclear factor kappa B (NF‐κB) p65 subunit (RELA), a canonical IL‐1 signal transducer, to be significantly active and potentially regulate many genes, including AR. We used small interfering RNA (siRNA) to silence the NF‐κB family of transcription factor subunits, RELA, RELB, c‐REL, NFKB1, or NFKB2, in IL‐1‐treated LNCaP, C4‐2, and C4‐2B PCa cell lines. C4‐2 and C4‐2B cell lines are castration‐resistant LNCaP sublines and represent progression toward metastatic PCa disease, and we have previously shown that IL‐1 represses AR mRNA levels in C4‐2 and C4‐2B cells.Results: siRNA revealed that RELA alone is sufficient to mediate IL‐1 repression of AR mRNA and AR activity. Intriguingly, while LNCaP cells are more sensitive to IL‐1‐mediated repression of AR than C4‐2 and C4‐2B cells, RELA siRNA led to a more striking derepression of AR mRNA levels and AR activity in C4‐2 and C4‐2B cells than in LNCaP cells.Conclusions: These data indicate that there are RELA‐independent mechanisms that regulate IL‐1‐mediated AR repression in LNCaP cells and suggest that the switch to RELA‐dependent IL‐1 repression of AR in C4‐2 and C4‐2B cells reflects changes in epigenetic and transcriptional programs that evolve during PCa disease progression.Keywords
All Related Versions
Funding Information
- National Institutes of Health (UL1TR001105)
- National Cancer Institute (K01CA160602, R21CA175798)
- University of Texas System
This publication has 30 references indexed in Scilit:
- Serum cytokine profiles in patients with prostate carcinomaExperimental and Therapeutic Medicine, 2011
- Aberrant Activation of the Androgen Receptor by NF-κB2/p52 in Prostate Cancer CellsCancer Research, 2010
- Reduced Tumor Necrosis Factor Receptor–Associated Death Domain Expression Is Associated with Prostate Cancer ProgressionCancer Research, 2009
- The NF- B Family of Transcription Factors and Its RegulationCold Spring Harbor Perspectives in Biology, 2009
- NF-κB Regulates Androgen Receptor Expression and Prostate Cancer GrowthThe American Journal of Pathology, 2009
- The Nuclear Factor-κB Pathway Controls the Progression of Prostate Cancer to Androgen-Independent GrowthCancer Research, 2008
- Interplay of Nuclear Factor-κB and B-myb in the Negative Regulation of Androgen Receptor Expression by Tumor Necrosis Factor αMolecular Endocrinology, 2008
- SIRNA-Directed In Vivo Silencing of Androgen Receptor Inhibits the Growth of Castration-Resistant Prostate CarcinomasPLOS ONE, 2007
- Unraveling androgen receptor interactomes by an array-based method: Discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptorExperimental Cell Research, 2006
- TUMOR NECROSIS FACTOR-α REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINEJournal of Urology, 2000